{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:03:51Z","timestamp":1794895431475,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Research Ward Excellence Program","award":["BRWEP2024W054070105"],"award-info":[{"award-number":["BRWEP2024W054070105"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2023IR27"],"award-info":[{"award-number":["2023IR27"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The study aimed to assess the predictive performance of transition zone PSA density (TZ-PSAD) compared to conventional PSA density (PSAD) in detecting clinically significant prostate cancer (csPCa) among patients with negative pre-biopsy MRI findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The study included 606 patients with negative MRI findings who subsequently underwent transrectal ultrasound-guided systematic biopsy. AI software automatically measured prostate and zonal volumes, from which PSAD and TZ-PSAD (total PSA\/transition zone volume) were calculated. Diagnostic performances were evaluated using ROC curve analysis, risk stratification was applied to select patients needing biopsy, and independent predictors of imaging-invisible csPCa were determined through univariate and multivariate analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      51 patients (8.4%) were diagnosed with csPCa. TZ-PSAD demonstrated significant superior discriminative ability (AUC\u2009=\u20090.718) compared to PSAD (AUC\u2009=\u20090.686;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019). Patients with TZ-PSAD\u2009\u2265\u20090.35\u2009ng\/mL\/cc had a csPCa detection rate of 20.1%, while those below this threshold had a rate of 4.1%. The optimal TZ-PSAD threshold of 0.35\u2009ng\/mL\/cc showed superior performance than the guideline-recommended PSAD threshold of 0.2\u2009ng\/mL\/cc. Multivariate analysis identified TZ-PSAD as a strong independent predictor of imaging-invisible csPCa.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TZ-PSAD outperforms conventional PSAD in predicting csPCa among men with negative MRI, offering a valuable tool for risk stratification. This facilitates individualized risk assessment, potentially reducing unnecessary biopsies and optimizing patient management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>Our AI system delivers accurate and reproducible prostate zone segmentation, while TZ-PSAD derived from AI outperforms conventional PSAD in detecting csPCa in MRI-negative patients and serves as an effective triage tool to optimize biopsy decision-making and reduce unnecessary systematic biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Our AI system enables accurate and reproducible segmentation and measurement of prostate zones.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>TZ-PSAD demonstrates significantly superior diagnostic performance over conventional PSAD for identifying men with a negative MRI who will have csPCa on a systematic biopsy.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>TZ-PSAD represents an effective triage metric to reduce unwarranted systematic biopsies in MRI-negative patients.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-026-02221-8","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:43:20Z","timestamp":1770731000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Artificial intelligence-derived transition zone PSA density as a triage tool to reduce unnecessary prostate systematic biopsies in MRI-negative men"],"prefix":"10.1186","volume":"17","author":[{"given":"Jiaheng","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengsheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingcheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-677X","authenticated-orcid":false,"given":"Kan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6711-6601","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2221_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, Van Den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 79:243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"Eur Urol"},{"key":"2221_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, Van Den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"2221_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bju.15277","volume":"127","author":"IG Schoots","year":"2021","unstructured":"Schoots IG, Padhani AR (2021) Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU Int 127:175\u2013178. https:\/\/doi.org\/10.1111\/bju.15277","journal-title":"BJU Int"},{"key":"2221_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/JU.0000000000001414","volume":"205","author":"J Buisset","year":"2021","unstructured":"Buisset J, Norris JM, Puech P et al (2021) Negative prebiopsy magnetic resonance imaging and risk of significant prostate cancer: baseline and long-term followup results. J Urol 205:725\u2013731. https:\/\/doi.org\/10.1097\/JU.0000000000001414","journal-title":"J Urol"},{"key":"2221_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12957-024-03420-7","volume":"22","author":"S Lin","year":"2024","unstructured":"Lin S, Jiang W, Ding J et al (2024) Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China. World J Surg Oncol 22:140. https:\/\/doi.org\/10.1186\/s12957-024-03420-7","journal-title":"World J Surg Oncol"},{"key":"2221_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/pros.24193","volume":"81","author":"G Liu","year":"2021","unstructured":"Liu G, Zhu Y, Yao Z, Jiang Y, Wu B, Bai S (2021) Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy. Prostate 81:983\u2013991. https:\/\/doi.org\/10.1002\/pros.24193","journal-title":"Prostate"},{"key":"2221_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2217\/fon-2021-1538","volume":"18","author":"M Chen","year":"2022","unstructured":"Chen M, Wang R, Zhang T, Zhang X, Wan Y, Fu X (2022) Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance. Future Oncol 18:1473\u20131483. https:\/\/doi.org\/10.2217\/fon-2021-1538","journal-title":"Future Oncol"},{"key":"2221_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.31","volume":"2","author":"B Chughtai","year":"2016","unstructured":"Chughtai B, Forde JC, Thomas DDM et al (2016) Benign prostatic hyperplasia. Nat Rev Dis Primer 2:16031. https:\/\/doi.org\/10.1038\/nrdp.2016.31","journal-title":"Nat Rev Dis Primer"},{"key":"2221_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-med-063014-123902","volume":"67","author":"EH Kim","year":"2016","unstructured":"Kim EH, Larson JA, Andriole GL (2016) Management of benign prostatic hyperplasia. Annu Rev Med 67:137\u2013151. https:\/\/doi.org\/10.1146\/annurev-med-063014-123902","journal-title":"Annu Rev Med"},{"key":"2221_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/pros.24863","volume":"85","author":"OT Esengur","year":"2025","unstructured":"Esengur OT, Stevenson E, Stecko H et al (2025) Assessing the impact of transition and peripheral zone PSA densities over whole-gland PSA density for prostate cancer detection on multiparametric MRI. Prostate 85:612\u2013624. https:\/\/doi.org\/10.1002\/pros.24863","journal-title":"Prostate"},{"key":"2221_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-87311-1","volume":"15","author":"Y Jin","year":"2025","unstructured":"Jin Y, Chen F, Xu G, Wei C, Dong C (2025) Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions. Sci Rep 15:3258. https:\/\/doi.org\/10.1038\/s41598-025-87311-1","journal-title":"Sci Rep"},{"key":"2221_CR12","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1007\/s00261-024-04301-z","volume":"49","author":"S Kuanar","year":"2024","unstructured":"Kuanar S, Cai J, Nakai H et al (2024) Transition-zone PSA-density calculated from MRI deep learning prostate zonal segmentation model for prediction of clinically significant prostate cancer. Abdom Radiol 49:3722\u20133734. https:\/\/doi.org\/10.1007\/s00261-024-04301-z","journal-title":"Abdom Radiol"},{"key":"2221_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1590\/S1677-5538.IBJU.2017.0506","volume":"44","author":"HAS Castro","year":"2018","unstructured":"Castro HAS, Iared W, Santos JEM, Solha RS, Shigueoka DC, Ajzen SA (2018) Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng\/mL. Int Braz J Urol 44:709\u2013716. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2017.0506","journal-title":"Int Braz J Urol"},{"key":"2221_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.clinimag.2019.12.010","volume":"60","author":"L Zhu","year":"2020","unstructured":"Zhu L, Gao G, Liu Y et al (2020) Feasibility of integrating computer-aided diagnosis with structured reports of prostate multiparametric MRI. Clin Imaging 60:123\u2013130. https:\/\/doi.org\/10.1016\/j.clinimag.2019.12.010","journal-title":"Clin Imaging"},{"key":"2221_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/jmri.26337","volume":"49","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Wei R, Gao G et al (2019) Fully automatic segmentation on prostate MR images based on cascaded fully convolution network. J Magn Reson Imaging 49:1149\u20131156. https:\/\/doi.org\/10.1002\/jmri.26337","journal-title":"J Magn Reson Imaging"},{"key":"2221_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958065","volume":"12","author":"L Zhu","year":"2022","unstructured":"Zhu L, Gao G, Zhu Y et al (2022) Fully automated detection and localization of clinically significant prostate cancer on MR images using a cascaded convolutional neural network. Front Oncol 12:958065. https:\/\/doi.org\/10.3389\/fonc.2022.958065","journal-title":"Front Oncol"},{"key":"2221_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/jmri.28608","volume":"58","author":"Z Sun","year":"2023","unstructured":"Sun Z, Wu P, Cui Y et al (2023) Deep-learning models for detection and localization of visible clinically significant prostate cancer on multi-parametric MRI. J Magn Reson Imaging 58:1067\u20131081. https:\/\/doi.org\/10.1002\/jmri.28608","journal-title":"J Magn Reson Imaging"},{"key":"2221_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00261-024-04241-8","volume":"49","author":"X Yin","year":"2024","unstructured":"Yin X, Wang K, Wang L et al (2024) Algorithms for classification of sequences and segmentation of prostate gland: an external validation study. Abdom Radiol 49:1275\u20131287. https:\/\/doi.org\/10.1007\/s00261-024-04241-8","journal-title":"Abdom Radiol"},{"key":"2221_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13244-023-01421-w","volume":"14","author":"Z Sun","year":"2023","unstructured":"Sun Z, Wang K, Kong Z et al (2023) A multicenter study of artificial intelligence-aided software for detecting visible clinically significant prostate cancer on mpMRI. Insights Imaging 14:72. https:\/\/doi.org\/10.1186\/s13244-023-01421-w","journal-title":"Insights Imaging"},{"key":"2221_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s41021-023-00280-7","volume":"45","author":"A Maeda-Minami","year":"2023","unstructured":"Maeda-Minami A, Nishikawa T, Ishikawa H et al (2023) Association of PSA variability with prostate cancer development using large-scale medical information data: a retrospective cohort study. Genes Environ 45:25. https:\/\/doi.org\/10.1186\/s41021-023-00280-7","journal-title":"Genes Environ"},{"key":"2221_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.prnil.2022.08.001","volume":"11","author":"M Kobayashi","year":"2023","unstructured":"Kobayashi M, Kijima T, Yashi M, Kamai T (2023) Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels. Prostate Int 11:27\u201333. https:\/\/doi.org\/10.1016\/j.prnil.2022.08.001","journal-title":"Prostate Int"},{"key":"2221_CR22","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.juro.2006.04.024","volume":"176","author":"LS Marks","year":"2006","unstructured":"Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG (2006) The interpretation of serum prostate specific antigen in men receiving 5\u03b1-reductase inhibitors: a review and clinical recommendations. J Urol 176:868\u2013874. https:\/\/doi.org\/10.1016\/j.juro.2006.04.024","journal-title":"J Urol"},{"key":"2221_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215\u2013224. https:\/\/doi.org\/10.1056\/NEJMoa030660","journal-title":"N Engl J Med"},{"key":"2221_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/01.ju.0000169255.64518.fb","volume":"174","author":"RD Etzioni","year":"2005","unstructured":"Etzioni RD, Howlader N, Shaw PA et al (2005) Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 174:877\u2013881. https:\/\/doi.org\/10.1097\/01.ju.0000169255.64518.fb","journal-title":"J Urol"},{"key":"2221_CR25","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1002\/jmri.29660","volume":"61","author":"Z Sun","year":"2025","unstructured":"Sun Z, Wang K, Gao G et al (2025) Assessing the performance of artificial intelligence assistance for prostate MRI: a two-center study involving radiologists with different experience levels. J Magn Reson Imaging 61:2234\u20132245. https:\/\/doi.org\/10.1002\/jmri.29660","journal-title":"J Magn Reson Imaging"},{"key":"2221_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244\u2013252. https:\/\/doi.org\/10.1097\/PAS.0000000000000530","journal-title":"Am J Surg Pathol"},{"key":"2221_CR27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Zelefsky MJ, Sjoberg DD et al (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69:428\u2013435. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.046","journal-title":"Eur Urol"},{"key":"2221_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bju.13427","volume":"118","author":"JS Wysock","year":"2016","unstructured":"Wysock JS, Mendhiratta N, Zattoni F et al (2016) Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results. BJU Int 118:515\u2013520. https:\/\/doi.org\/10.1111\/bju.13427","journal-title":"BJU Int"},{"key":"2221_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4103\/aja.aja_72_20","volume":"23","author":"C Wang","year":"2021","unstructured":"Wang C, Wang YY, Wang SY et al (2021) Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml\u20131. Asian J Androl 23:415\u2013420. https:\/\/doi.org\/10.4103\/aja.aja_72_20","journal-title":"Asian J Androl"},{"key":"2221_CR30","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00330-022-09239-8","volume":"33","author":"E Thimansson","year":"2022","unstructured":"Thimansson E, Bengtsson J, Baubeta E et al (2022) Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI. Eur Radiol 33:2519\u20132528. https:\/\/doi.org\/10.1007\/s00330-022-09239-8","journal-title":"Eur Radiol"},{"key":"2221_CR31","doi-asserted-by":"publisher","unstructured":"Haroon M, Sathiadoss P, Breau RH et al (2021) Proportion of clinically significant prostate cancer diagnosed by systematic template biopsy after negative pre-biopsy multiparametric magnetic resonance imaging and predictive value of prostate-specific antigen density. Can Urol Assoc J. https:\/\/doi.org\/10.5489\/cuaj.7455","DOI":"10.5489\/cuaj.7455"},{"key":"2221_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4103\/aja202220","volume":"24","author":"CC Zhang","year":"2022","unstructured":"Zhang CC, Tu X, Lin TH et al (2022) The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-na\u00efve men: clinical outcomes from a high-volume center in China. Asian J Androl 24:615\u2013619. https:\/\/doi.org\/10.4103\/aja202220","journal-title":"Asian J Androl"},{"key":"2221_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/17562872221088536","volume":"14","author":"LAMJG van Riel","year":"2022","unstructured":"van Riel LAMJG, Jager A, Meijer D et al (2022) Predictors of clinically significant prostate cancer in biopsy-na\u00efve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator. Ther Adv Urol 14:17562872221088536. https:\/\/doi.org\/10.1177\/17562872221088536","journal-title":"Ther Adv Urol"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02221-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-026-02221-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02221-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:02:13Z","timestamp":1770775333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-026-02221-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2221"],"URL":"https:\/\/doi.org\/10.1186\/s13244-026-02221-8","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Peking University First Hospital (2023-272).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The need for informed consent was waived due to the retrospective design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}